Product information and disease description Place of product in therapy Disease description Burden of Adenoid cystic carcinoma with solid histology or high-grade transformation

Economic burden and healthcare resource utilization

4 evidence topics · 4 sources

Summary: economic burden

No cost-of-illness or healthcare resource utilization study specific to ACC or to aggressive ACC in the United States was identified. In United States administrative claims data (2005 to 2007 index dates) for 6,812 participants with oral cavity, oropharyngeal, or salivary gland cancer, total annual healthcare spending in the year after diagnosis was $79,151 in the commercially insured population, and spending exceeded that of matched comparators by payer type ($71,732 commercial, $35,890 Medicare, $44,541 Medicaid). Multimodality treatment cost twice as much as single-modality treatment, and employed participants had 44.9 more short-term disability days than comparators. In a German patient-level cost-effectiveness analysis in head and neck ACC, adding a carbon ion boost to IMRT increased overall costs by €18,076 with an ICER of €26,863 per life-year gained.

Direct and indirect costs of oral cavity, oropharyngeal, and salivary gland cancers in the United States

“Total annual health care spending for OC/OP/SG patients during the year after the index diagnosis was $79,151 for the Commercial population. Health care costs were higher for OC/OP/SG cancer patients with Commercial Insurance ($71,732, n = 3,918), Medicare ($35,890, n = 2,303) and Medicaid ($44,541, n = 585) than the comparison group (all p < 0.01). Commercially-insured employees with cancer (n = 281) had 44.9 more short-term disability days than comparison employees (p < 0.01). Multimodality treatment was twice the cost of single modality therapy.” (opens the source at this quote in a new tab)
“Those patients receiving all three treatments (surgery, radiation, and chemotherapy) had the highest costs of cost of care, from $96,520 in the Medicare population to $153,892 in the Commercial population.” (opens the source at this quote in a new tab)

Radiotherapy costs in head and neck ACC: IMRT with carbon ion boost

“The experimental treatment increased overall costs by € 18,076 (€13,416 – €22,922) at a mean survival benefit of 0.86 years. Despite improved local control, following costs were also increased in the experimental treatment. The ICER was estimated to 26,863 €/LY.” (opens the source at this quote in a new tab)
“The combined treatment (IMRT+C12 boost) substantially increased initial and overall treatment cost.” (opens the source at this quote in a new tab)

Healthcare resource use: repeated treatment of recurrent and metastatic disease

“DSS was significantly prolonged after salvage surgery for both locoregional recurrence (p = 0.004) and lung metastatic recurrence (p = 0.012, vs best supportive care).” (opens the source at this quote in a new tab)

“A total of 51 patients were included in the study, of whom 36 (70.6%) received at least one line of systemic treatment.” (opens the source at this quote in a new tab)
“The median progression-free survival (PFS) was 7.82 months, 6.11 months, and 4.53 months for first-, second-, and third-line treatments, respectively. Disease progression was the primary reason for treatment discontinuation across all therapy lines.” (opens the source at this quote in a new tab)